Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, preve...

Descripción completa

Detalles Bibliográficos
Autores principales: Dockrell, Hazel M., McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Personal View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002045/
https://www.ncbi.nlm.nih.gov/pubmed/35427852
http://dx.doi.org/10.1016/j.ebiom.2022.103993
_version_ 1784685808815439872
author Dockrell, Hazel M.
McShane, Helen
author_facet Dockrell, Hazel M.
McShane, Helen
author_sort Dockrell, Hazel M.
collection PubMed
description The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
format Online
Article
Text
id pubmed-9002045
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90020452022-04-12 Tuberculosis vaccines in the era of Covid-19 – what is taking us so long? Dockrell, Hazel M. McShane, Helen EBioMedicine Personal View The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines. Elsevier 2022-04-12 /pmc/articles/PMC9002045/ /pubmed/35427852 http://dx.doi.org/10.1016/j.ebiom.2022.103993 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Personal View
Dockrell, Hazel M.
McShane, Helen
Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
title Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
title_full Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
title_fullStr Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
title_full_unstemmed Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
title_short Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
title_sort tuberculosis vaccines in the era of covid-19 – what is taking us so long?
topic Personal View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002045/
https://www.ncbi.nlm.nih.gov/pubmed/35427852
http://dx.doi.org/10.1016/j.ebiom.2022.103993
work_keys_str_mv AT dockrellhazelm tuberculosisvaccinesintheeraofcovid19whatistakingussolong
AT mcshanehelen tuberculosisvaccinesintheeraofcovid19whatistakingussolong

Ejemplares similares